Friend John E. II 4

What Happened

Kazia Therapeutics (KZIA) CEO John E. Friend II received two board-approved equity awards on January 8, 2026: 500,000 options over ADSs and 150,000 restricted share units (RSUs). The options carry an exercise price of $6.78 per ADS, were granted for no consideration, and expire on January 8, 2029. Both awards vest over time: one‑third vest on January 8, 2027 (the Commencement Date) and the remaining two‑thirds vest in equal yearly tranches on anniversaries thereafter. The RSUs represent a contingent right to receive one ADS per RSU upon vesting.

Key Details

• Transaction date: January 8, 2026 (reported on Form 4 filed July 8, 2026)
• Grants: 500,000 options (exercise price $6.78) and 150,000 RSUs
• Options expire: January 8, 2029
• Vesting: 1/3 on Jan 8, 2027; remaining 2/3 in equal yearly tranches thereafter (for both awards)
• Consideration: Options granted for no consideration (footnote F1); RSUs are board-approved awards (footnote F2)
• Shares owned after transaction: Not specified in the filing
• Filing timeliness: Report filed ~6 months after the grant date (late filing)

Context

These were grants (derivative awards), not purchases, exercises, or sales—no immediate cash proceeds or share transfers occurred. Options give the holder the right to buy ADSs at $6.78 until expiry; RSUs convert to ADSs one-for-one when they vest. Such awards are common executive compensation; the late filing delays public transparency but does not change the substance of the grants.